Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$30.72
-0.4%
$28.59
$21.97
$32.33
$1.32B1.62337,464 shs118,113 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.11
$4.65
$13.13
$1.10B1.471.15 million shs19.38 million shs
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$12.25
+1.5%
$15.10
$8.26
$19.41
$1.03B-0.011.26 million shs1.03 million shs
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
$29.88
-0.2%
$30.15
$25.86
$39.08
$266.10M1.328,510 shs81,071 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
-0.54%+0.47%+7.84%+32.19%+18.84%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.38%+101.00%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
+1.53%-4.56%-25.92%-5.08%+2.38%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-0.22%+5.34%+2.42%+7.50%+8.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artivion, Inc. stock logo
AORT
Artivion
2.539 of 5 stars
1.64.00.00.02.82.51.9
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.559 of 5 stars
1.10.00.00.01.42.50.6
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.2641 of 5 stars
4.50.00.00.01.44.20.6
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
1.9751 of 5 stars
3.51.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
3.17
Buy$32.405.47% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
3.00
Buy$26.89119.59% Upside
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
3.00
Buy$49.5065.69% Upside

Current Analyst Ratings Breakdown

Latest SMTI, LQDA, FNA, and AORT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Artivion, Inc. stock logo
AORT
Artivion
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
6/12/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.00
6/11/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $23.00
6/2/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/28/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $35.00
5/27/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/21/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/19/2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetMarket Perform ➝ Underperform$13.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$390.08M3.36$0.83 per share36.98$6.59 per share4.66
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
$14M74.77N/AN/A$0.91 per share13.46
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
$86.67M3.06N/AN/A$4.45 per share6.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
-$13.36M-$0.50N/A61.44N/A-5.49%3.63%1.34%8/6/2025 (Estimated)
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$9.66M-$1.34N/AN/AN/A-12.48%-29.22%-13.20%8/11/2025 (Estimated)

Latest SMTI, LQDA, FNA, and AORT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
-$0.31-$0.41-$0.10-$0.41$23.48 million$23.43 million
5/8/2025Q1 2025
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million
5/5/2025Q1 2025
Artivion, Inc. stock logo
AORT
Artivion
$0.12$0.06-$0.06-$0.01$94.81 million$98.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
N/AN/AN/AN/AN/A
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
1.08
5.53
3.95
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
2.08
2.93
2.91
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
1.18
2.77
2.54

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
64.54%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
8.10%

Insider Ownership

CompanyInsider Ownership
Artivion, Inc. stock logo
AORT
Artivion
7.60%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
26.50%
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
42.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,60042.70 million39.46 millionOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Liquidia Technologies, Inc. stock logo
LQDA
Liquidia Technologies
5085.49 million62.83 millionOptionable
Sanara MedTech Inc. stock logo
SMTI
Sanara MedTech
608.89 million5.10 millionNot Optionable

Recent News About These Companies

Sanara MedTech to Present at Investor Showcase

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artivion stock logo

Artivion NYSE:AORT

$30.72 -0.13 (-0.42%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$30.90 +0.18 (+0.59%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Liquidia Technologies stock logo

Liquidia Technologies NASDAQ:LQDA

$12.24 +0.19 (+1.53%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$12.24 0.00 (0.00%)
As of 07/3/2025 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Sanara MedTech stock logo

Sanara MedTech NASDAQ:SMTI

$29.88 -0.07 (-0.22%)
Closing price 07/3/2025 02:05 PM Eastern
Extended Trading
$29.88 0.00 (0.00%)
As of 07/3/2025 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.